A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

NCT03518073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease (AD)

Interventions

DRUG: Zagotenemab
DRUG: Placebo

Sponsor

Eli Lilly and Company